Clinically, asporin can be regarded as a serological biomarker to identify PTC patients with or without lymph node metastasis, and high expression of asporin in PTC tumorous tissues is a risk factor for poor prognosis. This evidence concerns the gene ASPN and metastatic malignant neoplasm in the lymph nodes.